BiotechTube
Incyclix Bio

Incyclix Bio

Durham, United States· Est.
incyclixbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $43M

Overview

Incyclix Bio is a private, clinical-stage biotechnology company developing selective CDK inhibitors for cancer, with a lead asset, INX-315, in Phase 1/2 trials for CDK4/6i-resistant breast cancer and CCNE1-amplified solid tumors. The company leverages deep, foundational expertise from the team that previously built G1 Therapeutics and advanced trilaciclib to market. Backed by a recent $11.25 million Series B extension and recognized as a 'Fierce 15' company, Incyclix aims to address a significant unmet need in overcoming resistance to first-generation CDK4/6 inhibitors.

Oncology

Technology Platform

Platform for discovery and development of selective small-molecule cyclin-dependent kinase (CDK) inhibitors, with deep expertise in CDK structural biology and pharmacology.

Funding History

2
Total raised:$43M
Series A$35M
Seed$8M

Opportunities

The primary opportunity is addressing the large and growing population of breast cancer patients resistant to first-generation CDK4/6 inhibitors, a multi-billion dollar market.
A secondary, high-value precision oncology opportunity exists in treating CCNE1-amplified solid tumors, such as ovarian cancer, where targeted options are limited.

Risk Factors

Key risks include clinical failure of the lead asset INX-315, intense competition from other companies developing CDK2 inhibitors, and the ongoing need to raise significant capital in a challenging biotech funding environment to advance development.

Competitive Landscape

The competitive landscape for CDK2 inhibitors is crowded and includes large pharma (e.g., AstraZeneca, Pfizer) and several biotech companies. Incyclix's differentiation relies on its team's deep CDK expertise and a focused clinical strategy in defined, high-need resistant populations.

More companies in Small Molecule Drugs →More companies in United States →